

Haematologica
HAEMATOL/2018/207068
Version 3

Utility of PET-CT in patients with chronic lymphocytic leukemia
following B-cell receptor pathway inhibitor therapy

Anthony R. Mato, William G. Wierda, Matthew S. Davids, Bruce D. Cheson, Steven E. Coutre, Michael Choi, Richard R. Furman, Leonard Heffner, Paul M. Barr, Herbert Eradat, Sharanya M. Ford, Lang Zhou, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, and John C. Byrd

Disclosures: A Mato: Institutional research funding: Pharmacyclics, Sunesis, Abbvie, TG therapeutics, Regeneron, DTRM, Acerta/AZ; Consultant for Pharmacyclics, Abbvie, Janssen, TG Therapeutics, Sunesis, Celgene, Gilead. WG Wierda: Research funding from AbbVie, Genentech; Consultant and speaker bureau for Genentech. MS Davids: Consultant and/or advisory board member for AbbVie, Genentech, Pharmacyclics, Janssen, TG Therapeutics, InCyte, Merck, Celgene, Astra-Zeneca, MEI Pharma; Institutional research funding from Genentech, Pharmacyclics, TG Therapeutics, BMS, MEI Pharma, Surface Oncology. BD Cheson: Paid consultancy for AbbVie, Roche-Genentech, Pharmacyclics, Acerta, Gilead, TG Therapeutics; Institution receives research support from Acerta, Pharmacyclics, Roche, AbbVie, TG Therapeutics. SE Coutre: Research funding from AbbVie. M Choi: Advisory board/consultancy for AbbVie; Institutional research funding from AbbVie; Speakers bureau for Gilead, AbbVie, Genentech, PCYC. RR Furman: Consultant for AbbVie, Acerta, Pharmacyclics, Loxo Oncology, Janssen, Gilead, Genentech, TG Therapeutics, Verastem, Sunesis, InCyte; speaker fees from Janssen. L Heffner: Institutional Research funding from Abbvie and Pharmacyclics. PM Barr: Consultancy for AbbVie, Gilead. H Eradat: Consultant for AbbVie, Gilead, Genentech; Advisory board member for AbbVie, Gilead, Genentech; Speaker for AbbVie, Gilead, Genentech. JC Byrd: Clinical trial support from Pharmacyclics and Acerta; Unpaid consultant for Genentech, AbbVie, Acerta, Pharmacyclics, Leukemia and Lymphoma Society LLC. SM Ford, L Zhou, M Verdugo, RA Humerickhouse, J Potluri: AbbVie employees and own stock.

Contributions: AM: designed the analysis, collected data, analyzed and interpreted data, wrote the manuscript. WGW: collected data, analyzed and interpreted data, wrote the manuscript. MSD: collected data, analyzed and interpreted data, wrote the manuscript. BDC: collected data, analyzed and interpreted data, wrote the manuscript. SEC: collected data, analyzed and interpreted data, wrote the manuscript. MC: collected data, analyzed and interpreted data, wrote the manuscript. RRF: collected data, analyzed and interpreted data, wrote the manuscript. LH: collected data, analyzed and interpreted data, wrote the manuscript. PMB: collected data, analyzed and interpreted data, wrote the manuscript. HE: collected data, analyzed and interpreted data, wrote the manuscript. SMF: analyzed and interpreted data, wrote the manuscript. LZ: analyzed and interpreted data, wrote the manuscript. MV: analyzed and interpreted data, wrote the manuscript. RAH: analyzed and interpreted data, wrote the manuscript. JP: designed the analysis, analyzed and interpreted data, wrote the manuscript. JCB: collected data, analyzed and interpreted data, wrote the manuscript.